8-K: Coherus BioSciences Completes UDENYCA Divestiture, Shifts Focus to Innovative Oncology Programs

Coherus BioSciences finalizes the sale of its UDENYCA franchise to Intas Pharmaceuticals for $483.4 million upfront, marking a strategic shift towards novel oncology programs.

Summary

• Coherus BioSciences completed the divestiture of its UDENYCA franchise to Intas Pharmaceuticals on April 11, 2025.
• The upfront consideration was $483.4 million in cash, including $118.4 million for UDENYCA product inventory.
• Coherus is eligible for two additional payments of $37.5 million each based on UDENYCA net sales targets.
• Approximately 40 Coherus employees transferred to Intas' U.S. subsidiary on April 14, 2025, to support UDENYCA.
• Coherus expects to repurchase its Convertible Notes on April 15, 2025.
• The company's biosimilar business, including CIMERLI, YUSIMRY, and UDENYCA, will be presented as discontinued operations.
• Coherus will focus on its innovative novel oncology programs including LOQTORZI, Casdozokitug, and CHS-114.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the completion of a strategic transaction, improved financial position, and focus on innovative oncology programs. However, the loss of revenue from UDENYCA and reliance on future pipeline success temper the overall optimism.

Positives

• The UDENYCA divestiture provides Coherus with $483.4 million in upfront cash.
• The company has the potential to receive an additional $75 million in milestone payments.
• Coherus' cash runway is extended into 2027 with a post-close cash balance of $250 million.
• The company can now focus on its innovative oncology pipeline and revenue-generating LOQTORZI product.
• Debt is dramatically reduced.

Negatives

• Coherus is losing the revenue stream from the UDENYCA franchise.
• The company is now reliant on the success of its remaining oncology pipeline.
• Milestone payments are contingent on Intas achieving specific net sales targets for UDENYCA.
• The company's entire biosimilar business, inclusive of the CIMERLI, YUSIMRY and UDENYCA franchises, will be presented as discontinued operations.

Risks

• Intas may not achieve the net sales thresholds required for Coherus to receive milestone payments.
• Transition services provided to Intas could disrupt Coherus' operations.
• The company may not realize the anticipated benefits of the transaction.
• Unforeseen liabilities could impact the company's future prospects.
• The market price of Coherus' common stock could be negatively affected.

Future Outlook

Coherus will focus on maximizing LOQTORZI revenues, advancing novel immuno-oncology candidates, and progressing label expanding indications for LOQTORZI in novel combinations.

Management Comments

• Denny Lanfear, Coherus Chairman and Chief Executive Officer, stated that the transaction has transformed the company, reduced debt, and provided ample runway to achieve mid-term corporate objectives.

Industry Context

This announcement reflects a trend in the biopharmaceutical industry of companies streamlining their portfolios to focus on core areas of expertise and higher-growth opportunities, particularly in the oncology space.

Comparison to Industry Standards

• Divesting non-core assets to focus on innovative pipelines is a strategy employed by companies like Amgen, which sold its biosimilars business to focus on innovative drugs.
• The upfront payment of $483.4 million is comparable to other deals in the biosimilar space, although the total value including milestones is relatively modest.
• Coherus' focus on LOQTORZI and other novel oncology programs aligns with the industry's shift towards personalized medicine and targeted therapies, similar to companies like Bristol Myers Squibb and Merck.

Stakeholder Impact

• Shareholders will benefit from the increased cash balance and focus on higher-growth opportunities.
• Employees who transferred to Intas will continue to support the UDENYCA franchise.
• Customers will experience a seamless transition of the UDENYCA franchise to Intas.
• Suppliers may be affected by the change in ownership of the UDENYCA franchise.
• Creditors will benefit from the reduced debt and improved financial stability of Coherus.

Next Steps

• Coherus will finalize adjustments to the upfront consideration.
• Intas will assume full responsibility for the UDENYCA franchise in the U.S.
• Coherus will continue to provide transition services to Intas.
• Coherus will focus on advancing its novel immuno-oncology candidates to key data milestones in 2026.
• Coherus will repurchase its Convertible Notes.

Key Dates

Keywords

UDENYCA, Coherus BioSciences, Intas Pharmaceuticals, Divestiture, Oncology, LOQTORZI, Biosimilar, Asset Sale, Financial Results